A dose ranging, randomized, double blind, parallel-group placebo-controlled multi-center study of RO5313534 used as add-on to donepezil treatment in patients with mild to moderate symptoms of Alzheimer's Disease.
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2016
At a glance
- Drugs RG 3487 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 16 Apr 2014 Data cleaning project 4: Deleted descriptor - donepezil (background therapy).
- 28 Apr 2012 Planned number of patients changed from 360 to 420 as reported by European Clinical Trials Database record